Biological and clinical assessment of a new bisphosphonate, (chloro-4 phenyl) thiomethylene bisphosphonate, in the treatment of Paget's disease of bone.

No abstract is available for this paper.

• Publication year

  1988

• Venue

  Bone

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/8756-3282(88)90115-9PMID 3073800
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of diphosphonates on the synthesis of prostaglandins in cultured calvaria cells

  2006cited by this paper
• Kinetic studies of bone and mineral metabolism during treatment with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) in rats

  2006cited by this paper
• Enhancement of the inhibitory action of APD on the transformation of osteoclast precursors into resorbing cells after dimethylation of the amino group.

  1987cited by this paper
• Efficacious management with aminobisphosphonate (APD) in Paget's disease of bone.

  1987cited by this paper
• Long-term follow-up observations on treatment in Paget's disease of bone.

  1987cited by this paper
• Experimental basis for the use of bisphosphonates in Paget's disease of bone.

  1987cited by this paper
• Paget's disease of bone treated in five days with AHPrBP (APD) per Os

  1987cited by this paper
• Efficacy of the bisphosphonate APD in the control of Paget's bone disease.

  1985cited by this paper
• Clinical experience with the use of two diphosphonates in the treatment of Paget's disease.

  1985cited by this paper
• Effects of 1-hydroxyethylidene-1,1 bisphosphonate and (chloro-4 phenyl) thiomethylene bisphosphonic acid (SR 41319) on the mononuclear cell factor-mediated release of neutral proteinases by articular chondrocytes and synovial cells.

  1985cited by this paper
• Secondary hyperparathyroidism associated with dichloromethane diphosphonate treatment of Paget's disease.

  1982cited by this paper
• Differential action of the bisphosphonates (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) and disodium dichloromethylidene bisphosphonate (Cl2MDP) on rat macrophage-mediated bone resorption in vitro.

  1982cited by this paper
• Effects of ethane-1 hydroxy-1, 1-diphosphonate (5 mg/kg/day dose) on quantitative bone histology in Paget's disease of bone.

  1981cited by this paper
• Calcitonin and diphosphonate in the treatment of Paget's disease of bone.

  1981cited by this paper
• Effects of disodium dichloromethylene diphosphonate (CL2MDP) on Paget's disease of bone.

  1980cited by this paper
• APD in Paget's disease of bone. Role of the mononuclear phagocyte system?

  1980cited by this paper
• Bone histomorphometry in Paget's disease. Quantitative and dynamic analysis of pagetic and nonpagetic bone tissue.

  1980cited by this paper
• Radioimmunoassay for the vitamin K-dependent protein of bone and its discovery in plasma.

  1980cited by this paper
• Effects of disodium dichloromethylene diphosphonate on Paget's disease of bone.

  1979cited by this paper
• DIAGNOSTIC PROCEDURES IN DISORDERS OF CALCIUM METABOLISM

  1978cited by this paper
• Sodium etidronate in the treatment of Paget's disease of bone. A study of long-term results.

  1977cited by this paper
• Osteoclast ultrastructure in Paget’s disease

  1976cited by this paper
• Nuclear inclusions in Paget's disease of bone.

  1976cited by this paper
• Results of prolonged treatment of Paget's disease of bone with disodium ethane-1-hydroxy-1, 1-diphosphonate (EHDP).

  1974cited by this paper
• Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans).

  1973cited by this paper
• The influence of two diphosphonates on calcium metabolism in the rat.

  1972cited by this paper
• Diphosphonates Inhibit Hydroxyapatite Dissolution in vitro and Bone Resorption in Tissue Culture and in vivo

  1969cited by this paper
• A new "kinetic" method for enzyme analysis suitable for automation.

  1969cited by this paper

• Hub Genes, Diagnostic Model, and Predicted Drugs Related to Iron Metabolism in Alzheimer's Disease

  2022cites this paper
• α-Heteroatom-substituted gem-Bisphosphonates: Advances in the Synthesis and Prospects for Biomedical Application

  2019cites this paper
• Paget's disease.

  2014cites this paper
• Bisphosphonates for Paget's disease of bone in adults.

  2014cites this paper
• [Italian guidelines for the diagnosis and treatment of Paget's disease of bone].

  2011cites this paper
• Pain in Paget's disease: a retrospective study of treatment efficacy.

  2011cites this paper
• Linee guida per la diagnosi e la terapia del morbo di Paget Italian guidelines for the diagnosis and treatment of Paget's disease of bone

  2007cites this paper
• Bisphosphonates modulate the effect of macrophage-like cells on osteoblast.

  2002cites this paper
• Guidelines on the management of Paget's disease of bone.

  2002cites this paper
• Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption.

  2000cites this paper
• Ultrastructural Properties of Bone Mineral of Control and Tiludronate-Treated Osteoporotic Rat

  2000cites this paper
• Cellular and molecular mechanisms of action of bisphosphonates

  2000cites this paper
• Risedronate, a Highly Effective, Short-Term Oral Treatment for Paget's Disease: A Dose-Response Study

  1999cites this paper
• Tiludronate. A new treatment for an old ailment: Paget's disease of bone.

  1999cites this paper
• A randomized, double-blind comparison of risedronate and etidronate in the treatment of paget’s disease of bone

  1999cites this paper
• A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group.

  1999cites this paper
• Risedronate, a highly effective oral agent in the treatment of patients with severe Paget's disease.

  1998cites this paper
• Paget's disease of bone: reduction of disease activity with oral risedronate.

  1998cites this paper
• The prevention and treatment of osteoporosis.

  1998cites this paper
• Paget's disease of bone: benefits of neridonate as a first treatment and in cases of relapse after clodronate.

  1998cites this paper
• Comparison of the efficacy and bioequivalence of two oral formulations of tiludronate in the treatment of Paget's disease of bone.

  1997cites this paper
• Multiple dose pharmacokinetics of tiludronate in healthy volunteers

  1996cites this paper
• Duration of response with oral clodronate in Paget's disease of bone.

  1996cites this paper
• The methodology of clinical trials of oral tiludronate in Paget's disease of bone.

  1995cites this paper
• Clinical features and pharmacologic treatment of Paget's disease.

  1995cites this paper
• Synthesis of disodium [benzene-U-14C]-(4-chlorophenylthio)methylenediphosphonate, [benzene-U-14C]-tiludronate

  1995cites this paper
• Tiludronate therapy for Paget's disease of bone.

  1995cites this paper
• Efficacy and safety of drugs for Paget's disease of bone.

  1995cites this paper
• Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone.

  1995cites this paper
• Tiludronate: bone pharmacology and safety.

  1995cites this paper
• Skeletal safety of tiludronate.

  1995cites this paper
• Therapeutic strategy in Paget's disease of bone.

  1995cites this paper
• Bisphosphonates in development for metabolic bone disease

  1994cites this paper
• Efficacy and tolerability of a new formulation of oral tiludronate (tablet) in the treatment of paget's disease of bone

  1994cites this paper
• Effects of tiludronate on bone mass, structure, and turnover at the epiphyseal, primary, and secondary spongiosa in the proximal tibia of growing rats after sciatic neurectomy

  1994cites this paper
• Effects of two novel bisphosphonates on bone cells in vitro.

  1994cites this paper
• Role of bisphosphonates in metabolic bone diseases.

  1993cites this paper
• Determinants of remission of paget's disease of bone

  1993cites this paper
• Bisphosphonates: Mechanisms of Action and Clinical Use

  1993cites this paper
• Paget's disease of bone treated with a five day course of oral tiludronate.

  1993cites this paper
• Evaluation of the efficacy and safety of oral tiludronate in Paget's disease of bone. A double-blind, multiple-dosage, placebo-controlled study.

  1992cites this paper
• Oral tiludronate: pharmacological properties and potential usefulness in Paget's disease of bone and osteoporosis.

  1992cites this paper
• Longitudinal effect of tiludronate on bone mineral density, resonant frequency, and strength in monkeys

  1992cites this paper
• The effect of nasal hCT on bone turnover in Paget's disease of bone--implications for the treatment of other metabolic bone diseases.

  1992cites this paper
• Effects of tiludronate on bone loss in paraplegic patients

  1992cites this paper
• BM 21.0955, a potent new bisphosphonate to inhibit bone resorption

  1991cites this paper
• [Spectacular effect of tiludronate in osteoporosis circumscripta cranii].

  1991cites this paper
• Efficacy and safety of the bisphosphonate tiludronate for the treatment of tumor-associated hypercalcemia.

  1991cites this paper
• Matrix vesicle calcification of ectopically induced osteoid tissue in 1-hydroxethylidene-1,1-bisphosphonate (HEBP)-treated mice.

  1990cites this paper
• Advances in the Management of Paget’s Disease of Bone

  1990cites this paper
• Prevention of postmenopausal bone loss by tiludronate

  1989cites this paper